Treatment of huntington disease with a cholinergic agonist

John G. Nutt, Arnold Rosin, Thomas N. Chase

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


The involuntary movements of Huntington disease may be related to cholinergic hypofunction in the striatum. For this reason, the effect of a direct cholinergic agonist, arecoline, was studied in six patients with this disorder. Rather than improving the chorea, arecoline tended to exacerbate the choreic movements. Arecoline did produce significant alterations of blood pressure, heart rate, and body temperature, probably by central cholinergic stimulation.

Original languageEnglish (US)
Pages (from-to)1061-1064
Number of pages4
Issue number10
StatePublished - Oct 1978
Externally publishedYes

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Treatment of huntington disease with a cholinergic agonist'. Together they form a unique fingerprint.

Cite this